Company profile: PanTher Therapeutics
1.1 - Company Overview
Company description
- Provider of localized cancer therapies leveraging the Sagittari platform to optimize drug dose and duration for high-dose, tumor-targeted treatment with minimal systemic exposure. Offers PTM-101, a clinical-stage candidate delivering high concentrations of paclitaxel to pancreatic tumors via minimally invasive laparoscopy, and exploratory programs for pancreatic, colon, and lung cancers.
Products and services
- Sagittari Platform: A proprietary drug development platform that optimizes dose and duration, enabling localized, high-dose tumor treatment with minimal systemic exposure for enhanced therapeutic response
- PTM-101: A clinical-stage drug candidate for pancreatic cancer that delivers high concentrations of paclitaxel directly to the tumor via a minimally invasive laparoscopic procedure for localized efficacy
- Pipeline Opportunities: Exploratory programs leveraging the Sagittari platform to develop localized treatments across pancreatic, colon, and lung cancer indications, architected to reduce systemic exposure and optimize therapeutic duration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PanTher Therapeutics
Pheon Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pheon Therapeutics company profile →
Precede Bio
HQ: United States
Website
- Description: Provider of liquid biopsy and epigenomic profiling solutions that analyze circulating chromatin and the DNA methylome from 1 mL of plasma to evaluate gene and pathway activation. Offerings include blood-based diagnostic tests for precision use of cancer medicines as a minimally invasive alternative to tissue biopsies, an assay revealing disease biology and therapeutic targets for research and therapy selection, and a RUO platform for drug developers and academic researchers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precede Bio company profile →
AvenCell Therapeutics
HQ: United States
Website
- Description: Provider of switchable and allogeneic CAR-T cell therapy platforms, including a Universal Switchable CAR with soluble targeting modules for hematologic malignancies and solid tumors; a CRISPR/Cas9-based platform enabling off-the-shelf CAR-T that overcomes graft-versus-host disease and immune rejection; and therapies AVC-101 (CD123 autologous) and AVC-201 (allogeneic UniCAR) for relapsed/refractory AML.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AvenCell Therapeutics company profile →
Day One Bio
HQ: United States
Website
- Description: Provider of targeted therapies for life-threatening diseases, including OJEMDA (tovorafenib), FDA-approved for children with BRAF-altered relapsed or progressive pediatric low-grade glioma; advancing investigational MAPK-pathway inhibitors tovorafenib and pimasertib and conducting FIREFLY-1/2 and FIRELIGHT-1 trials in brain and solid tumors with MAPK pathway aberrations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day One Bio company profile →
Tesaro
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical solutions dedicated to improving the lives of cancer patients, leveraging management expertise to identify, acquire and develop promising drug candidates and to commercialize safer, more effective cancer therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tesaro company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PanTher Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PanTher Therapeutics
2.2 - Growth funds investing in similar companies to PanTher Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PanTher Therapeutics
4.2 - Public trading comparable groups for PanTher Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →